Insulet stock (US45784P1012): Strong Q1 growth and raised guidance lift shares

Insulet reported a 34% sales jump in Q1 2026 and raised its full?year revenue guidance, sending its stock higher in pre?market trading.

Insulet stock has moved higher after the diabetes?care device maker reported a 34% year?over?year sales increase in the first quarter of 2026 and raised its full?year revenue guidance, signaling continued momentum in its Omnipod insulin?delivery business. The company’s shares ticked up about 5% in pre?market trading on Nasdaq, reflecting investor optimism around the stronger?than?expected results and the upward revision to growth targets, according to market data cited by Drug Delivery Business as of May 09, 2026.

For the three months ended March 31, 2026, Insulet posted revenue of $761.7 million and net profit of $91.1 million, or $1.30 per share, beating Wall Street consensus estimates, the company said in its first?quarter earnings release summarized by Drug Delivery Business as of May 09, 2026. The 34% top?line growth reflects broad adoption of the Omnipod platform across both type 1 and type 2 diabetes patients, as well as continued expansion in international markets.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Insulet Corporation
• Sector/industry: Medical devices, diabetes care
• Headquarters/country: Acton, Massachusetts, United States
• Core markets: United States, Europe, Canada, and other international regions
• Key revenue drivers: Omnipod insulin?delivery systems, recurring consumables, and new product launches
• Home exchange/listing venue: Nasdaq (ticker: PODD)
• Trading currency: U.S. dollar

Insulet: core business model

Insulet designs, manufactures, and sells tubeless insulin?delivery systems for people with insulin?dependent diabetes, primarily through its Omnipod product line. The Omnipod platform is a wearable, tubeless insulin pump that adheres to the skin and delivers insulin continuously, with the option for bolus doses at mealtimes, according to StockStory as of May 09, 2026. This approach aims to simplify diabetes management compared with traditional tubed pumps and multiple daily injections.

The company’s business model combines hardware sales with recurring revenue from consumables such as pods and accessories, which are typically replaced every few days. This recurring?consumables structure supports more predictable cash flows and higher lifetime value per customer, a feature that is attractive to investors in the medical?device space, as noted by StockAnalysis as of May 09, 2026. Insulet also invests in software and connectivity features that integrate with continuous glucose monitors and mobile apps to enhance user experience.

Main revenue and product drivers for Insulet

Insulet’s primary revenue driver is the Omnipod family of insulin?delivery systems, which includes both standalone pumps and integrated automated?insulin?delivery platforms. The company has been expanding indications and approvals for Omnipod in both type 1 and type 2 diabetes, broadening its addressable patient base, according to BioSpace as of May 09, 2026. Recent clinical initiatives, such as the EVOLVE pivotal study for a fully closed?loop system in type 2 diabetes, underscore Insulet’s push into more advanced automated?insulin?delivery solutions.

International expansion and new product launches also contribute to revenue growth. Insulet has been increasing its presence in Europe and other regions, where reimbursement and regulatory pathways for insulin pumps are evolving, according to StockAnalysis as of May 09, 2026. At the same time, the company continues to iterate on its Omnipod platform with features such as improved algorithms, longer?wearing pods, and enhanced connectivity, which help differentiate its offering from competitors in the diabetes?care device market.

Conclusion

Insulet’s strong first?quarter performance and raised full?year guidance highlight the resilience of its Omnipod?based business model in a competitive diabetes?care landscape. The 34% revenue growth and improved profitability suggest that the company is successfully converting new patients and expanding its installed base, which could support further top?line expansion if execution remains consistent, according to Drug Delivery Business as of May 09, 2026.

For US investors, Insulet offers exposure to the growing diabetes?care device sector, where demand is underpinned by rising diabetes prevalence and the shift toward more advanced, automated insulin?delivery systems. However, the stock remains sensitive to reimbursement changes, competitive pressures, and the pace of new product approvals, which could weigh on future growth if not managed effectively, as highlighted by BioSpace as of May 09, 2026. As with any equity, investors should weigh both the growth potential and the sector?specific risks before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.